Reuters logo
BRIEF-TG Therapeutics announces completion of target enrollment
September 5, 2017 / 11:46 AM / 3 months ago

BRIEF-TG Therapeutics announces completion of target enrollment

Sept 5 (Reuters) - TG Therapeutics Inc:

* TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial

* TG Therapeutics Inc - ‍unity-CLL phase 3 trial is being conducted pursuant to a special protocol assessment (SPA) agreement with FDA

* TG Therapeutics Inc - ‍enrollment is expected to continue until mid-October​

* TG Therapeutics Inc- expect to deliver top-line data on ORR endpoint earlier than anticipated, now expected in Q2 of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below